Switching from Ocrelizumab to Rituximab in RRMS: Protocol Recommendations
When switching from maintenance ocrelizumab to rituximab in RRMS, no washout period is required, and rituximab should be initiated using standard maintenance dosing (500 mg every 6 months) rather than re-induction, as both are anti-CD20 agents with similar mechanisms and overlapping B-cell depletion effects.
Timing of the Switch
Initiate rituximab within 24 weeks after the last ocrelizumab infusion, based on clinical evaluation, but no sooner than 16 weeks after the last ocrelizumab dose 1.
The French MS Society guidelines support switching from second-line therapies like ocrelizumab to other agents after a 3-month washout period 2, though this may be conservative given the shared mechanism of action between ocrelizumab and rituximab.
For patients on maintenance ocrelizumab (typically every 6 months), the switch can occur at the time of the next scheduled infusion without additional delay 2.
Dosing Protocol: Maintenance vs. Re-induction
Use maintenance dosing, not re-induction:
Administer rituximab 500 mg as two infusions separated by 2 weeks, then continue 500 mg every 6 months 1.
Re-induction with the standard 375 mg/m² weekly for 4 weeks protocol is not necessary because:
Monitoring B-Cell Repopulation
B-cell counts (CD19/CD20) should be checked before the switch to ensure adequate depletion from ocrelizumab 3.
The presence of B-cells (CD19 and/or CD20 counts ≥1%) increases the risk of infusion-related reactions by approximately 5-fold on the first rituximab infusion 3.
If significant B-cell repopulation has occurred (≥1% or ≥80 cells/μL), this does not contraindicate the switch but warrants enhanced premedication and monitoring 3, 4.
Premedication Protocol
Standard premedication is essential:
Administer acetaminophen and an antihistamine before each rituximab infusion 1.
Consider methylprednisolone 100 mg IV or equivalent 30 minutes prior to reduce infusion-related reactions, particularly if B-cells are detectable 1, 3.
Safety Considerations
Infusion-related reactions (IRRs) occur in approximately 12-14% of patients switching from rituximab to ocrelizumab, with similar rates expected in the reverse direction 3.
The risk of IRRs is highest with the first rituximab infusion after switching (Day 1), lower at Day 15, and returns to baseline by Week 24 3.
Continue PCP prophylaxis during and for at least 6 months following rituximab treatment, particularly in patients with prior prolonged B-cell depletion 1.
Monitor for hypogammaglobulinemia, as rituximab may carry a higher long-term risk compared to ocrelizumab 5.
Clinical Efficacy Expectations
No loss of efficacy is expected when switching from ocrelizumab to rituximab, as both demonstrate equivalent effectiveness in RRMS 6.
Studies show no significant difference in annualized relapse rate, time to first relapse, confirmed disability worsening, or MRI activity between ocrelizumab and rituximab 6.
Patients switching from first-line therapies to rituximab demonstrate reduced inflammatory activity on MRI and decreased CSF neurofilament light chain levels 7.
Common Pitfalls to Avoid
Do not delay the switch unnecessarily beyond 24 weeks from the last ocrelizumab dose, as this may allow disease reactivation 1.
Do not use the full 4-week induction protocol (375 mg/m² weekly × 4) unless the patient has had prolonged B-cell recovery or documented disease activity 1.
Do not assume antibody cross-reactivity: Antidrug antibodies to ocrelizumab do not predict rituximab IRRs 3.